Xiaojun Deng,Jian Chu,Bo Yang,Feng Liu,Weifeng Wang,Jidong Hao,Jiansheng Wan,Hui Liu. Is extended biopsy protocol justified in all patients with PSA ≥ 20 ng/mL?. Oncol Transl Med, 2014, 13: 422-426. |
Is extended biopsy protocol justified in all patients with PSA ≥ 20 ng/mL? |
Received:July 01, 2014 Revised:August 18, 2014 |
View Full Text View/Add Comment Download reader |
KeyWord:biopsy; prostate cancer (PCa); extend; detection rate; prostate-specific antigen (PSA) |
Author Name | Affiliation | E-mail | Xiaojun Deng | Pudong New Area Zhoupu Hospital, Shanghai 201318, China | deng810729@126.com | Jian Chu | The 411 Hospital of People's Liberation Army, Shanghai 200081, China | | Bo Yang | Department of Urology, Pudong New Area Zhoupu Hospital, Shanghai 201318, China | | Feng Liu | Department of Urology, Pudong New Area Zhoupu Hospital, Shanghai 201318, China | | Weifeng Wang | Department of Urology, Pudong New Area Zhoupu Hospital, Shanghai 201318, China | | Jidong Hao | Department of Urology, Pudong New Area Zhoupu Hospital, Shanghai 201318, China | | Jiansheng Wan | Department of Urology, Pudong New Area Zhoupu Hospital, Shanghai 201318, China | | Hui Liu | Pudong New Area Zhoupu Hospital, Shanghai 201318, China | liuhui600706@126.com |
|
Hits: 7330 |
Download times: 7499 |
Abstract: |
Objective: The aim of this study was to investigate whether it was necessary to increase the number of cores at initial prostate biopsy with patients of prostate-specific antigen (PSA) ≥ 20 ng/mL and to explore an appropriate individualized
transrectal ultrasonograhpy (TRUS)-guided prostate biopsy for the detection of prostate cancer in men suspicious of prostate cancer. Methods: A total of 115 patients with PSA ≥ 20 ng/mL and suspicious of prostate cancer were prospectively randomized to perform TRUS-guided biopsy. Patients were randomized to a “6 X” cores or a “10 X” cores protocol. The primary end point was cancer detection rate. Secondary end points were cancer characteristics, rate of complications and the level of pain experienced by patients during TRUS-guided prostate biopsy. Results: Preoperative variables were similar in both groups. The overall prostate cancer detection rate was 73.9%. The “10 X” cores strategy increased cancer detection rate only 9.7% in patients with PSA ≥ 20 ng/mL but < 50 ng/mL, while there was no difference between the two strategies for cancer detection in patients with PSA ≥ 50.1 ng/mL. The number of extended biopsy cores and pain score of extended biopsy in prostate cancer patients increased significantly (P < 0.001). Conclusion: Our findings suggest that there is no significant advantage in using extended biopsy protocol in all patients with PSA ≥ 20 ng/mL. |
Close |
|
|
|